Companies / Galectin Therapeutics Inc / Activity
Activity — Galectin Therapeutics Inc
58 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Jamil Khurram Executive | Sell | Common Stock | $239.2K | -47K -100.00% | 0 0.00% of shares | medium |
| Jan 6, 2026 | Lewis Joel CEO | Sell | Common Stock | $134.9K | -38K -4.33% | 832,592 1.26% of shares | medium |
| Jun 29, 2026 | Jamil Khurram Executive | Exercise | Common Stock | $118.7K | +47K | 47,467 0.07% of shares | low |
| Jun 29, 2026 | Shlevin Harold H. Director | Sell | Common Stock | $112.2K | -22K -77.41% | 6,500 <0.01% of shares | medium |
| Jan 5, 2026 | Lewis Joel CEO | Sell | Common Stock | $108.3K | -28K -3.09% | 870,290 1.32% of shares | medium |
| Jan 5, 2026 | Callicutt Jack W Executive | Sell | Common Stock | $100.3K | -26K -47.92% | 27,968 0.04% of shares | medium |
| Jan 5, 2026 | Jamil Khurram Executive | Sell | Common stock | $99.4K | -25K -54.32% | 21,446 0.03% of shares | low |
| Jan 6, 2026 | Jamil Khurram Executive | Sell | Common Stock | $78.2K | -21K -100.00% | 0 0.00% of shares | low |
| Jan 2, 2026 | Lewis Joel CEO | Sell | Common Stock | $77.9K | -19K -2.03% | 898,021 1.36% of shares | low |
| Jan 6, 2026 | Callicutt Jack W Executive | Sell | Common Stock | $74.7K | -20K -72.78% | 7,614 0.01% of shares | low |
| Jan 2, 2026 | Callicutt Jack W Executive | Sell | Common Stock | $58.4K | -14K -20.58% | 53,700 0.08% of shares | low |
| Jan 2, 2026 | Jamil Khurram Executive | Sell | Common Stock | $54.8K | -13K -21.76% | 46,945 0.07% of shares | low |
| Jan 16, 2026 | Uihlein Richard E Director | Grant | Common Stock | $40.0K | +13K +0.13% | 10,332,676 15.69% of shares | low |
| Jun 26, 2026 | Shlevin Harold H. Director | Sell | Common Stock | $38.7K | -8K -54.33% | 6,500 <0.01% of shares | low |
| Dec 31, 2025 | Jamil Khurram Executive | Sell | Common Stock | $33.1K | -8K -100.00% | 0 0.00% of shares | low |
| Jun 29, 2026 | Shlevin Harold H. Director | Exercise | Common Stock | $27.4K | +22K +342.58% | 28,768 0.04% of shares | low |
| Jun 23, 2026 | Jamil Khurram Executive | Sell | Common Stock | $23.7K | -8K -100.00% | 0 0.00% of shares | low |
| Jun 26, 2026 | Jamil Khurram Executive | Sell | Common Stock | $12.7K | -3K -100.00% | 0 0.00% of shares | low |
| Jun 26, 2026 | Jamil Khurram Executive | Sell | Common Stock | $10.2K | -2K -100.00% | 0 0.00% of shares | low |
| Dec 31, 2025 | Jamil Khurram Executive | Exercise | Common Stock | $10.0K | +8K | 8,125 0.01% of shares | low |
| Jun 26, 2026 | Shlevin Harold H. Director | Exercise | Common Stock | $9.5K | +8K +118.95% | 14,232 0.02% of shares | low |
| Jun 23, 2026 | Jamil Khurram Executive | Exercise | Common Stock | $9.3K | +8K | 7,557 0.01% of shares | low |
| Jun 26, 2026 | Jamil Khurram Executive | Exercise | Common Stock | $6.3K | +3K | 2,533 <0.01% of shares | low |
| Jun 26, 2026 | Jamil Khurram Executive | Exercise | Common Stock | $4.5K | +2K | 2,037 <0.01% of shares | low |
| May 26, 2026 | Jamil Khurram Executive | Sell | Common Stock | $1.8K | -568 -100.00% | 0 0.00% of shares | low |
| Feb 6, 2026 | Eldred Kary Director | Buy | Common Stock | $810 | +300 +0.46% | 65,682 0.10% of shares | low |
| May 26, 2026 | Jamil Khurram Executive | Exercise | Common Stock | $699 | +568 | 568 <0.01% of shares | low |
| Jan 2, 2026 | Lewis Joel CEO | Exercise | Common Stock | $0 | +84K +10.09% | 916,592 1.39% of shares | low |
| Jan 2, 2026 | Callicutt Jack W Executive | Exercise | Common Stock | $0 | +60K +788.02% | 67,614 0.10% of shares | low |
| Jan 2, 2026 | Jamil Khurram Executive | Exercise | Common Stock | $0 | +60K | 60,000 0.09% of shares | low |
| Jun 29, 2026 | Shlevin Harold H. Director | Exercise | Stock Option (right to buy) | — | -22K -42.60% | 30,000 0.05% of shares | low |
| Jun 26, 2026 | Shlevin Harold H. Director | Exercise | Stock Option (right to buy) | — | -8K -12.89% | 52,268 0.08% of shares | low |
| Jun 29, 2026 | Jamil Khurram Executive | Exercise | Stock Option (right to buy) | — | -47K -100.00% | 0 0.00% of shares | low |
| Jun 26, 2026 | Jamil Khurram Executive | Exercise | Stock Option (right to buy) | — | -3K -5.07% | 47,467 0.07% of shares | low |
| Jun 26, 2026 | Jamil Khurram Executive | Exercise | Stock option (right to buy) | — | -2K -2.00% | 100,000 0.15% of shares | low |
| Jun 23, 2026 | Jamil Khurram Executive | Exercise | Stock option (right to buy) | — | -8K -18.87% | 32,500 0.05% of shares | low |
| May 26, 2026 | Jamil Khurram Executive | Exercise | Stock option (right to buy) | — | -568 -1.40% | 40,057 0.06% of shares | low |
| Jan 16, 2026 | Zordani Richard A. Jr. Director | Grant | Stock option (right to buy) | — | +60K | 60,000 0.09% of shares | low |
| Jan 16, 2026 | Schwartz Elissa J. Director | Grant | Stock option (right to buy) | — | +60K | 60,000 0.09% of shares | low |
| Jan 16, 2026 | Carson Benjamin Sr Director | Grant | Stock option (right to buy) | — | +60K | 60,000 0.09% of shares | low |
| Jan 16, 2026 | Lewis Joel CEO | Grant | Restricted Stock Unit | — | +120K | 100,000 0.15% of shares | low |
| Jan 16, 2026 | Lewis Joel CEO | Grant | Stock option (right to buy) | — | +84K | 65,000 0.10% of shares | low |
| Jan 2, 2026 | Lewis Joel CEO | Exercise | Restricted Stock Unit | — | -84K -100.00% | 0 0.00% of shares | low |
| Jan 16, 2026 | Lewis Joel CEO | Grant | Stock option (right to buy) | — | +91K | 91,000 0.14% of shares | low |
| Jan 16, 2026 | Uihlein Richard E Director | Grant | Stock option (right to buy) | — | +60K | 60,000 0.09% of shares | low |
| Jan 16, 2026 | Shlevin Harold H. Director | Grant | Stock option (right to buy) | — | +60K | 60,000 0.09% of shares | low |
| Jan 16, 2026 | Eldred Kary Director | Grant | Stock option (right to buy) | — | +60K | 60,000 0.09% of shares | low |
| Jan 16, 2026 | Freeman Kevin D Director | Grant | Stock option (right to buy) | — | +60K | 60,000 0.09% of shares | low |
| Mar 12, 2026 | Brem Henry Director | Grant | Stock option (right to buy) | — | +60K | 60,000 0.09% of shares | low |
| Jan 16, 2026 | Callicutt Jack W Executive | Grant | Restricted Stock Unit | — | +100K | 100,000 0.15% of shares | low |